Sun Pharma Share Price Today: All drugs listed - check how they are doing and what is likely to happen
Sun Pharmaceutical's efforts around specialty portfolio ramp up are yielding favourable progress as prescription trends around the key products suggest growth on a QoQ basis. Levulan which was significantly below pre COVID levels has broadly normalized but Nirmal Bang says needs to monitor the impact of resurgence in COVID cases. In fact, seeing faint signals of an unfavourable impact of the second COVID wave as trends seems to suggest weakening prescription volumes across product categories in the last week of November.
Nirmal Bang maintains their estimates with valuation multiple of 23x based on September FY23E earnings at target price of Rs 618:Reuters